20 September 2024
Syncona
Limited
John Roche Appointed as a
Non-Executive Director
Syncona Ltd, (the "Company"), a
leading life science investor focused on creating, building and
scaling a portfolio of global leaders in life science, announces
the appointment of John Roche as an independent Non-Executive
Director, with effect from 1 October 2024.
John brings many years of broad
financial experience to the role, having spent more than 15 years
as a Partner at PricewaterhouseCoopers ("PwC") in Guernsey. During
this time he served as managing partner of the Guernsey office for
seven years and was leader of the Capital Markets Practice for
twelve years. While at PwC, John specialised in providing audit and
capital markets advisory services to listed investment companies
and alternative asset management clients, developing extensive
valuation experience.
John is a Fellow of the Institute of
Chartered Accountants in Ireland, who retired from practice in
2022. He is a Non-Executive Director and Chair of the Audit
Committee of Riverstone Energy Limited, a London-listed investment
company, and a Guernsey resident.
On appointment, John will join the
Company's Audit Committee.
Melanie Gee, Chair of Syncona Ltd, said:
"We are delighted to welcome John to Syncona. He
brings significant financial experience to the Board, and we look
forward to benefitting from his breadth of knowledge and expertise
as we support the Syncona team to deliver our long-term strategy
and growth ambitions."
John Roche said: "I am
delighted to be joining Syncona. I look forward to working closely
with my Board colleagues and the broader Syncona team as they
continue to invest to extend and enhance human life."
No further details are required to
be disclosed under UKLR 6.4.8R.
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus
Witt
Tel: +44 (0) 20 3981 7912
About Syncona
Syncona's purpose is to invest to
extend and enhance human life. We do this by creating, building and
scaling companies to deliver transformational treatments to
patients in areas of high unmet need.
We aim to build and maintain a
diversified portfolio of 20-25 globally leading life science
businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on
developing treatments that deliver patient impact by working in
close partnership with world-class academic founders and
experienced management teams. Our balance sheet underpins our
strategy, enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options,
build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.
Syncona Limited seeks to achieve
returns over the long term. Investors should seek to ensure they
understand the risks and opportunities of an investment in Syncona
Limited, including the information in our published documentation,
before investing.